Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

SHA - 337,000 Orion Corporation A shares converted into B shares

Company: Orion Oyj Date: 2025-08-20 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 337,000 Orion Corporation A shares converted into B shares

# 337,000 Orion Corporation A shares converted into B shares

ORION CORPORATION  

STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE  

20 AUGUST 2025 at 9.00 EEST  

        

**337,000 Orion Corporation A shares converted into B shares**

In accordance with Section 3 of the Articles of Association of Orion Corporation, 337,000 A shares have been converted into 337,000 B shares. The conversion has been entered into the Trade Register on 20 August 2025.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,971,783 A shares and 109,162,495 B shares. The number of votes of the company's shares is after the conversion 748,598,155.

Orion Corporation

|     |     |     |     |
| --- | --- | --- | --- |
| Liisa Hurme  <br><br>  <br><br>President and CEO |     | Mikko Kemppainen  <br><br>  <br><br>General Counsel |     |

**Contact person:**  

Tuukka Hirvonen, Head of Investor Relations, tel. +358 10 426 2721  

                                                 

**Publisher:**  

Orion Corporation  

Communications  

Orionintie 1A, FI-02200 Espoo, Finland  

[http://www.orionpharma.com](https://www.globenewswire.com/Tracker?data=CiFITsh3uD_11YoToqupCdQGuIoWcenbqtRh1uxyhy4t8wo8vXFSaAjwRGliDz2nhdRUuYQ5v3oKz-enSUuFVSJzj226o330tAsZbEy5x8I2ILNa7szjjSUkYbrQRVbH)

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

![](https://www.globenewswire.com/newsroom/ti?nf=MTAwMTEyMzY5MCM0MDIyMDA2NTMjMjAwMTk2Mw==)  

![](https://ml-eu.globenewswire.com/media/NjQzZmRiNGQtOGFhZS00YjQ3LWE5MjEtNTJhMjNkMmU4MWU3LTEwMTM1MzYtMjAyNS0wOC0yMC1lbg==/tiny/Orion-Oyj.png)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now